Oxford BioDynamics (LON:OBD) Trading Down 0.4% – Time to Sell?

Oxford BioDynamics Plc (LON:OBD)’s share price was down 0.4% on Friday . The company traded as low as GBX 0.53 ($0.01) and last traded at GBX 0.56 ($0.01). Approximately 12,095,048 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 31,534,662 shares. The stock had previously closed at GBX 0.57 ($0.01).

Oxford BioDynamics Price Performance

The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The business’s fifty day moving average price is GBX 0.77 and its 200-day moving average price is GBX 2.22. The stock has a market capitalization of £9.90 million, a price-to-earnings ratio of -0.09 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last released its quarterly earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.